中位生存期

其中局限期病人1年、2年、5年生存率分别为54%、30.3%和18.2%，中位生存期为14.5个月；

In the limited stage ( LS ) group , the survival rates were 54.5 % for 1 year , 30.0 % for 2 year and 18.2 % for 5 year , MST was 14.5 months .

临床受益反应率（clinicalbenefitresponse，CBR）高达923%；中位生存期70个月；

The clinical benefit response ( CBR ) was 92 3 % and the median survival was 7 0 months .

第6组的中位生存期明显长于其余各组，P0.01。

The median survival in group 6 was conspicuously longer compared to the other groups ( P0.01 ) .

在国家免费抗病毒治疗实施3年内，接受抗病毒治疗AIDS患者中位生存期已经延长了2年。

During the 3-year-long implementation period of free anti-virus therapy , the survival period of AIDS patients receiving anti-virus therapy has been extended for 2 years .

结论TP方案治疗晚期鼻咽癌肝、肺转移疗效明显优于DF方案，中位生存期TP组也高于DF组。

Conclusion The treatment effect and median survival in TP regiment group were apparently higher than those in DF regiment group .

比较复发率的同时进行复发时间生存率和中位生存期。结果：在改善临床症状，生活质量上，治疗组明显高于对照组（P0.05）。

Simultaneously compare the recurrence rate and median survival time of recurrence survivalResults : In improving clinical symptoms , quality of life , the treatment group was significantly higher ( P0.05 ) .

结论初始VAD方案化疗有效者预后较好，中位生存期可达43.1个月，加用骨膦治疗可延长生存期。

Conclusions That VAD regimen is effective in inductive chemotherapy suggests a good prognosis and the median survival time is 43.1 months .

结论对ⅢA期NSCLC患者进行新辅助化疗可提高手术切除率，延长患者中位生存期，提高患者2年生存率。

Conclusion Neoadjuvant chemotherapy can improve surgery resection rate and increase the median period of survival and 2 year survival rate in patients with stage ⅲ A NSCLC .

B组，中位生存期为10.2个月，其中31例（57.4%）在2～4次TAI和/或TAE后显示胆道梗阻再通。

In group B , mean survival period was 10.2 months with recanalization of biliary obstruction shown in 31 cases ( 57.4 % ) following 2-4 times of TAI and / or TAE .

两组整体肿瘤退缩率为67.2%，A、B组分别为81.8%和51.6%；中位生存期12.5个月，A、B组患者2年生存率分别为35.3%和12.1%。

The response rates of the patients and the 2-year overall survival rates in group A were 81.8 % and 51.6 % , respectively , and were 35.3 % and 12.1 % in group B. The low-dose fractionated CRT was superior than accelerated CRT .

一般来说，MPE的预后较差，MPE确诊后的中位生存期从3个月到12个月不等，平均生存期大约为6个月。

MPE median survival following diagnosis ranges from 3 to 12 months . The average life span of MPE patients is about 6 months .

HAI组与TACE组的1年生存率和中位生存期相比较（69%比73%，70周比75周），TACE组均优于HAI组，该治疗方法有效。

Between the HAI group and TACE group , the existent ratio of one year aud existence period 69 % vs 73 % , 70w vs 75w ; the TACE group are better than the HAI group .

结果客观缓解率18.2%，中位生存期5.3个月，KPS评分明显改善42.4%，仅4例患者出现轻度毒性反应。

Results Objective remission rate was 18.2 % . Median survival duration was 5.3 months . KPS score of prominent improvement was 42.4 % and only 4 patients had mild toxic response .

结论①术后化疗虽不能显著延长ⅢA-N2期NSCLC患者的中位生存期，但显著提高了1年、2年生存率。

Conclusion Postoperative adjuvant chemotherapy dose not significantly improve median survival among patients with completely resected stage ⅲ A-N2 NSCLC , but significantly improves the 1 - and 2-year survival rate .

TACE联合瘤内无水酒精注射（PEI）治疗36例，1,3年生存率分别为100.0%和66.5%，中位生存期为3.5年。

Thirty six out of 130 patients treated with TACE plus percutaneous ethanol injection ( PEI ), the 1 , 3 year survival rates were 100.0 % and 66.5 % respectively with a median survival time ( MST ) of 3.5 years .

中位生存期分别为65个月和8个月，经统计学处理差异无显著性（P005）。

The median overall survival time were 6 5 months in group A and 8 months in group B ( P 0 05 ) .

结果全组局部病灶控制率为68.3%（56/82），中位生存期（MST）为12.5个月。初治和复治者MST分别为19.5和9.5个月。

Results The local control rate was 68.3 % ( 56 / 82 ) and median survival time ( MST ) was 12.5 months for all patients , 19.5 months for newly diagnosed patients and 9.5 months for recurrent patients .

XRT组与RT组的3年总生存率分别为33.3%和19.1%，无肿瘤进展生存率分别为21.4%和16.6%，两组的中位生存期分别为19和14个月。

The 3-year overall survival rate and disease-free survival rate in XRT group and RT group were 33.3 % , 19.1 % and 21.4 % , 16.6 % , respectively . The median survival time was 19 months and 14 months respectively .

结论低剂量5-Fu、HCPT腹腔化疗联合平消片口服治疗晚期肝癌不良反应轻，部分患者肿瘤缩小，生存质量提高，中位生存期明显延长。

Conclusion The poisonous and side reaction of intraperitoneal chemotherapy with low amount of 5-Fu and HCPT combining with taking orally Ping Xiao pian in advanced hepatic carcinoma were not serious . The tumor were shrinking in some patients . The quality of life was enhanced .

结果81例肺内转移者中位生存期（MST）及1、2、3年生存率（SR）分别为13个月（95%CI11~15），57%、21%、7%；

Results Median survival time ( MST ) and 1 - , 2 - , 3-year survival rate ( SR ) for patients with sole intrapulmonary metastasis were 13 months ( 95 % CI : 11 & 15 ), 57 % , 21 % , 7 % , respectively ;

结果：CR2例，PR18例，总有效率为48.8%，中位生存期39周，一年生存率为36.6%，中位进展时间21周。

Results : Complete response was observed in 2 patients , partial response in 18 patients , with an overall response rate of 48.8 % . The median survival period was 39 weeks . 1-year survial rate was 36.6 % .

根治性切除组、姑息性切除组、姑息性旁路引流组、单纯手术探查组、未手术组的中位生存期分别为304d、138d、134d、123d、86d。

The median survival time in patients undergoing radical resection , palliative surgical resection , bypass , surgical exploration and none of operations was 304 , 138 , 134 , 123 and 86 d , respectively .

随访至1996年8月底，CHEP组存活16例，CHOP组存活15例，中位生存期为24个月和20个月。

Having been followed to the end of August , 1996 , 16 patients in the CHEP group and 15 patients in the CHOP group were alive with respective median survivals 24 ( 3 ~ 66 ) months and 20 ( 2 ~ 48 ) months .

结果：治疗组CR12例，PR8例，NC6例，PD6例，中位生存期126个月，1年生存率563%（18/32）。

RESULTS : In cure group , CR was 12 case , PR 8 case , NC 6 case , PD 6 case , and the median survival time was 12 6 month , the 1 year survival rate 56 3 % ( 18 / 32 ) .

手术治疗组7例，无住院死亡，中位生存期14月。

The median survival time of surgical group was 14 months .

随访15个月，中位生存期为6个月。

A median survive period was 6 months follow-up 15 months .

三组中位生存期分别为10个月、9个月和8个月（P>0.05）；

Median survival times were 10 , 9 and 8 months ;

疗局限期患者中位生存期16个月。

The mid - survival period of was 16 months .

三种手术方式的中位生存期分别为5，16，28个月。

The median survival time was5,16,28 months , respectively .

结果全组中位生存期为20个月；

Results The median survival was 20 months .